

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

RECEIVED

MAY 01 2002

TECH CENTER 1600/2900

STEVEN LEE HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM



April 22, 2002

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

**COPY OF PAPERS
ORIGINALLY FILED**

**CERTIFICATE OF MAILING
37 C.F.R. § 1.8**

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below:

April 23, 2002
Date

Steven L. Highlander

Commissioner for Patents
Washington DC 20231

RE: *U.S. Patent Application No. 10/045,594 "METHODS AND COMPOSITIONS RELATING TO MUSCLE SPECIFIC SARCOMERIC CALCINEURIN-BINDING PROTEINS (CALSARCINS)" - Eric Olson and Norbert Frey (Our Reference: UTSD:729US)*


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C17).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10110099/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl.: as noted

25158698.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eric Olson
Norbert Frey

Serial No.: 10/045,594

Filed: November 7, 2001

For: METHODS AND COMPOSITIONS
RELATING TO MUSCLE SPECIFIC
SARCOMERIC CALCINEURIN-
BINDING PROTEINS (CALSARCINS)

Group Art Unit: 1645

Examiner: Unknown


Atty. Dkt. No.: UTSD:729US/SLH

RECEIVED

MAY 01 2002

TECH CENTER 1600/2900

COPY OF PAPERS
ORIGINALLY FILED

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
April 23, 2002	
Date	Steven J. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10110099/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Steven L. Highlander", is written over the typed name and registration number.

Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: April 23, 2002

Form PTO-1449 (modified)

List of Patents and Publications of Applicant
 INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSD:729US/SLH

Serial No.

10/045,594

Applicant

Eric Olson

Norbert Frey

Filing Date:

November 7, 2001

Group:

1615

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

RECEIVED

MAY 01 2002

TECH CENTER 1600/2900

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Ding <i>et al.</i> , "Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin," <i>Circ Res.</i> , 84(6):729-734, 1999.
	C2	Hill <i>et al.</i> , "Cardiac hypertrophy is not a required compensatory response to short-term pressure overload," <i>Circulation</i> , 101(24):2863-2869, 2000.
	C3	Lim <i>et al.</i> , "Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy," <i>Circulation</i> , 101(20):2431-2437, 2000.
	C4	Lim <i>et al.</i> , "Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition," <i>J Mol Cell Cardiol</i> , 32(4):697-709, 2000.
	C5	Marban <i>et al.</i> , "Intracellular free calcium concentration measured with 19F NMR spectroscopy in intact ferret hearts," <i>Proc Natl Acad Sci U S A</i> , 84:6005-6009, 1987.
	C6	Seidman and Seidman, "Molecular genetic studies of familial hypertrophic cardiomyopathy," <i>Basic Res Cardiol</i> , 93 Suppl 3:13-16, 1998.
	C7	Shimoyama <i>et al.</i> , "Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy," <i>Circulation</i> , 100(24):2449-2454, 1999.
	C8	Sussman <i>et al.</i> , "Prevention of cardiac hypertrophy in mice by calcineurin inhibition," <i>Science</i> , 281:1690-1693, 1998.
	C9	Zhang <i>et al.</i> , "Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats," <i>Circ Res.</i> , 84(6):722-728, 1999.

25132083.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

COPY OF PAPERS
ORIGINALLY FILED

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.
UTSD:729US/SLHSerial No.
10/045,594Applicant
Eric Olson
Norbert FreyFiling Date:
November 7, 2001Group:
1615U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
*See Page 1*RECEIVED
MAY 01 2002
TECH CENTER 1600/2900**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C10	GenBank accession number AA036142
	C11	GenBank accession number AA176945
	C12	GenBank accession number AA197193
	C13	GenBank accession number AC008453.3
	C14	GenBank accession number AW000988
	C15	GenBank accession number AW742494
	C16	GenBank accession number AW964108
	C17	GenBank accession number W29466

COPY OF PAPERS
ORIGINALLY FILED

25132083.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)